An expert discusses the treatment approach for recurrence in Case 1, evaluating the combination of toripalimab + gemcitabine/cisplatin for recurrent disease and considering the potential for ...

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...

Montpellier, France Monday, March 10, 2025, 15:00 Hrs [IST] ...

A panelist discusses how treatment strategies for recurrent nasopharyngeal carcinoma (NPC) have evolved, with the updated NCCN guidelines now recommending toripalimab plus gemcitabine/cisplatin as ...

Researchers are investigating whether a common cholesterol drug could be repurposed to treat HPV-positive cervical cancer.

Q4 2024 Earnings Call Transcript March 10, 2025 Fennec Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is ...

Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, ...

In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Feb. 27 in ...

Analysts at HC Wainwright upped their Q1 2025 earnings estimates for shares of Fennec Pharmaceuticals in a research note issued to investors on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju ...

Good morning ladies and gentlemen, and welcome to Fennec Pharmaceuticals fourth quarter and full year 2024 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's ...

INVINCIBLE-3 Study, and 25 patients have been screened Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several ...

Amid a rapidly evolving landscape in the treatment of muscle-invasive bladder cancer (MIBC), new findings presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California, ...